verified SJR 7,948 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Elsevier Inc.

workspace_premium Q1 — Medicine (miscellaneous) lock Subscription Unclaimed

Journal of Thoracic Oncology

Journal of Thoracic Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 190. It has an SJR impact factor of 7,948 and it has a best quartile of Q1. It has an SJR impact factor of 7,948.

Journal of Thoracic Oncology focuses its scope in these topics and keywords: lung, cancer, patients, cell, smallcell, nsclc, treatment, malignant, expression, chemotherapy, ...

ISSN: 1556-0864

Editorial: Elsevier Inc.

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Portal NPD menu_book Guidelines NPD

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

7,948 Q1

H-index 190

Tasa de Aceptación pie_chart

22% Selectiva

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

NPD Subscription

Ruta Non-OA NPD

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

7,948

H-index

190

Docs (year)

253

Docs 3y

741

Total refs

5503

Cites 3y

6704

Citable 3y

353

Cites/Doc 2y

7.97

Ref/Doc

21.75

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Cell Cycle-Associated Kinases as Targets for Therapy in Lung Cancer

Welcome to the Chicago Multidisciplinary Symposium in Thoracic Oncology

Epidermal Growth Factor Receptor Pathway

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for the Diagnosis of Intrapulmonary Lesions

EML4/ALK and Ras Inhibitors

Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer

Cost-Effectiveness of Follow-Up for Subsolid Pulmonary Nodules in High-Risk Patients

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience

Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib

Clinical Effectiveness of Boron Neutron Capture Therapy for a Recurrent Malignant Peripheral Nerve Sheath Tumor in the Mediastinum

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach

Chemotherapy in Patients =80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6

SHOW MORE ARTICLES

Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

Cancer Stem Cells and Targeting Embryonic Signaling Pathways

BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis

Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium

Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges

Best of the Month: A Round Up of Articles Published in Recent Months

Alpha1-Antitrypsin Deficiency Carriers, Serum Alpha 1-Antitrypsin Concentration, and Non-small Cell Lung Cancer Survival

Alpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non-Small Cell Lung Cancer

Adjuvant Chemotherapy Uptake in Non-small Cell Lung Cancer

Acetylcholine Receptor Pathway and Lung Cancer

A Phase III Randomized Trial of Gemcitabine-Oxaliplatin versus Carboplatin-Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.